Variable | Progression free survival | Overall survival | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | |
Age | 1.003 | 0.988–1.019 | 0.653 | 1.001 | 0.985–1.018 | 0.871 |
Gender, male | 0.936 | 0.677–1.293 | 0.688 | 0.829 | 0.586–1.173 | 0.290 |
KPS, < 80 | 1.064 | 0.520–2.177 | 0.864 | 0.577 | 0.212–1.569 | 0.281 |
Presenting symptom | 1.292 | 0.770–2.168 | 0.332 | 2.256 | 1.247–4.082 | 0.007 |
Tumor location, left | 1.027 | 0.753–1.400 | 0.867 | 1.073 | 0.769–1.497 | 0.678 |
ROD, ≥ 1.34 | 3.974 | 2.784–5.673 | < 0.001 | 2.783 | 1.927–4.018 | < 0.001 |
Number of metastatic organs, ≥ 2 | 1.053 | 0.728–1.547 | 0.468 | 0.459 | 0.592–1.426 | 0.584 |
pT stage, 3/4 | 1.021 | 0.677–1.676 | 0.061 | 1.025 | 0.823–1.312 | 0.078 |
WHO/ISUP grade, III/IV | 2.308 | 1.684–3.165 | < 0.001 | 3.164 | 2.249–4.415 | < 0.001 |
Tumor necrosis | 1.438 | 1.031–2.007 | 0.032 | 1.677 | 1.167–2.410 | 0.007 |
Sarcomatoid differentiation | 2.131 | 1.455–3.120 | < 0.001 | 1.722 | 1.107–2.680 | 0.016 |
MSKCC score, intermediate and poor | 2.624 | 1.895–3.634 | < 0.001 | 3.125 | 2.174–4.493 | < 0.001 |
IMDC score, intermediate and poor | 3.342 | 2.116–6.528 | < 0.001 | 4.317 | 2.383–6.657 | < 0.001 |